Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9905157 | Cancer Genetics and Cytogenetics | 2005 | 4 Pages |
Abstract
Deletions of the 5â² ABL region adjacent to the t(9;22)(q34;q11) have recently been reported in 8-32.7% of patients with chronic myeloid leukemia (CML). The deletions were visualized with fluorescence in situ hybridization using, in the majority of the cases, the Vysis LSI BCR/ABL ES (extra signal) probe. In our series, 10 of 99 CML patients (10.1%) were characterized by a 5â² ABL deletion. We show that 3â² BCR losses are observed in nearly all the cases with 5â² ABL deletions. Moreover, the different genetic events (Philadelphia chromosome formation; 5â² ABL and 3â² BCR deletions) occur simultaneously in a one-step process without any evidence for genetic instability in the target bone marrow cells.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mickaël Fournier, Stéphanie Lacrosse, Mauricette Jamar, Vincent Bours, Christian Herens,